Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Using Target Engagement Biomarkers to Predict Clinical Efficacy of MetAP2 Inhibitors.

Farrell PJ, Zopf CJ, Huang HJ, Balakrishna D, Holub C, Bilakovics J, Fanjul A, Matuszkiewicz J, Plonowski A, Rolzin P, Banerjee U, Ermolieff J, Cheruvallath ZS, McBride C, Bartkowski D, Mazur C, Pachori A, Larson CJ.

J Pharmacol Exp Ther. 2019 Nov;371(2):299-308. doi: 10.1124/jpet.119.259028. Epub 2019 Sep 19.

PMID:
31537613
2.

MetAP2 inhibition increases energy expenditure through direct action on brown adipocytes.

Huang HJ, Holub C, Rolzin P, Bilakovics J, Fanjul A, Satomi Y, Plonowski A, Larson CJ, Farrell PJ.

J Biol Chem. 2019 Jun 14;294(24):9567-9575. doi: 10.1074/jbc.RA118.007302. Epub 2019 May 2.

PMID:
31048375
3.

CX3CL1-Fc treatment prevents atherosclerosis in Ldlr KO mice.

Riopel M, Vassallo M, Ehinger E, Pattison J, Bowden K, Winkels H, Wilson M, de Jong R, Patel S, Balakrishna D, Bilakovics J, Fanjul A, Plonowski A, Larson CJ, Ley K, Cabrales P, Witztum JL, Olefsky JM, Lee YS.

Mol Metab. 2019 Feb;20:89-101. doi: 10.1016/j.molmet.2018.11.011. Epub 2018 Dec 2.

4.

Chronic fractalkine administration improves glucose tolerance and pancreatic endocrine function.

Riopel M, Seo JB, Bandyopadhyay GK, Li P, Wollam J, Chung H, Jung SR, Murphy A, Wilson M, de Jong R, Patel S, Balakrishna D, Bilakovics J, Fanjul A, Plonowski A, Koh DS, Larson CJ, Olefsky JM, Lee YS.

J Clin Invest. 2018 Apr 2;128(4):1458-1470. doi: 10.1172/JCI94330. Epub 2018 Mar 5.

5.

Time-dependent inhibition of PHD2.

Tcholakov I, Grimshaw CE, Shi L, Kiryanov A, Murphy ST, Larson CJ, Plonowski A, Ermolieff J.

Biosci Rep. 2017 Jun 30;37(3). pii: BSR20170275. doi: 10.1042/BSR20170275. Print 2017 Jun 30.

6.

Discovery of Highly Potent Liver X Receptor β Agonists.

Kick EK, Busch BB, Martin R, Stevens WC, Bollu V, Xie Y, Boren BC, Nyman MC, Nanao MH, Nguyen L, Plonowski A, Schulman IG, Yan G, Zhang H, Hou X, Valente MN, Narayanan R, Behnia K, Rodrigues AD, Brock B, Smalley J, Cantor GH, Lupisella J, Sleph P, Grimm D, Ostrowski J, Wexler RR, Kirchgessner T, Mohan R.

ACS Med Chem Lett. 2016 Oct 23;7(12):1207-1212. eCollection 2016 Dec 8.

7.

Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 1.

Cheruvallath Z, Tang M, McBride C, Komandla M, Miura J, Ton-Nu T, Erikson P, Feng J, Farrell P, Lawson JD, Vanderpool D, Wu Y, Dougan DR, Plonowski A, Holub C, Larson C.

Bioorg Med Chem Lett. 2016 Jun 15;26(12):2774-2778. doi: 10.1016/j.bmcl.2016.04.073. Epub 2016 Apr 25.

PMID:
27155900
8.

Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 2.

McBride C, Cheruvallath Z, Komandla M, Tang M, Farrell P, Lawson JD, Vanderpool D, Wu Y, Dougan DR, Plonowski A, Holub C, Larson C.

Bioorg Med Chem Lett. 2016 Jun 15;26(12):2779-2783. doi: 10.1016/j.bmcl.2016.04.072. Epub 2016 Apr 25.

PMID:
27136719
9.

The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.

Foster P, Yamaguchi K, Hsu PP, Qian F, Du X, Wu J, Won KA, Yu P, Jaeger CT, Zhang W, Marlowe CK, Keast P, Abulafia W, Chen J, Young J, Plonowski A, Yakes FM, Chu F, Engell K, Bentzien F, Lam ST, Dale S, Yturralde O, Matthews DJ, Lamb P, Laird AD.

Mol Cancer Ther. 2015 Apr;14(4):931-40. doi: 10.1158/1535-7163.MCT-14-0833. Epub 2015 Jan 30.

10.

Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRβ.

Kick E, Martin R, Xie Y, Flatt B, Schweiger E, Wang TL, Busch B, Nyman M, Gu XH, Yan G, Wagner B, Nanao M, Nguyen L, Stout T, Plonowski A, Schulman I, Ostrowski J, Kirchgessner T, Wexler R, Mohan R.

Bioorg Med Chem Lett. 2015 Jan 15;25(2):372-7. doi: 10.1016/j.bmcl.2014.11.029. Epub 2014 Nov 15.

PMID:
25435151
11.

Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.

Yu P, Laird AD, Du X, Wu J, Won KA, Yamaguchi K, Hsu PP, Qian F, Jaeger CT, Zhang W, Buhr CA, Shen P, Abulafia W, Chen J, Young J, Plonowski A, Yakes FM, Chu F, Lee M, Bentzien F, Lam ST, Dale S, Matthews DJ, Lamb P, Foster P.

Mol Cancer Ther. 2014 May;13(5):1078-91. doi: 10.1158/1535-7163.MCT-13-0709. Epub 2014 Mar 14.

12.

Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).

Takeuchi CS, Kim BG, Blazey CM, Ma S, Johnson HW, Anand NK, Arcalas A, Baik TG, Buhr CA, Cannoy J, Epshteyn S, Joshi A, Lara K, Lee MS, Wang L, Leahy JW, Nuss JM, Aay N, Aoyama R, Foster P, Lee J, Lehoux I, Munagala N, Plonowski A, Rajan S, Woolfrey J, Yamaguchi K, Lamb P, Miller N.

J Med Chem. 2013 Mar 28;56(6):2218-34. doi: 10.1021/jm3007933. Epub 2013 Mar 7.

PMID:
23394126
13.

Discovery of XL413, a potent and selective CDC7 inhibitor.

Koltun ES, Tsuhako AL, Brown DS, Aay N, Arcalas A, Chan V, Du H, Engst S, Ferguson K, Franzini M, Galan A, Holst CR, Huang P, Kane B, Kim MH, Li J, Markby D, Mohan M, Noson K, Plonowski A, Richards SJ, Robertson S, Shaw K, Stott G, Stout TJ, Young J, Yu P, Zaharia CA, Zhang W, Zhou P, Nuss JM, Xu W, Kearney PC.

Bioorg Med Chem Lett. 2012 Jun 1;22(11):3727-31. doi: 10.1016/j.bmcl.2012.04.024. Epub 2012 Apr 16. Erratum in: Bioorg Med Chem Lett. 2012 Aug 1;22(15):5157.

PMID:
22560567
14.

Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.

Leahy JW, Buhr CA, Johnson HW, Kim BG, Baik T, Cannoy J, Forsyth TP, Jeong JW, Lee MS, Ma S, Noson K, Wang L, Williams M, Nuss JM, Brooks E, Foster P, Goon L, Heald N, Holst C, Jaeger C, Lam S, Lougheed J, Nguyen L, Plonowski A, Song J, Stout T, Wu X, Yakes MF, Yu P, Zhang W, Lamb P, Raeber O.

J Med Chem. 2012 Jun 14;55(11):5467-82. doi: 10.1021/jm300403a. Epub 2012 May 17.

PMID:
22548342
15.

Discovery and characterization of an inhibitor of glucosylceramide synthase.

Richards S, Larson CJ, Koltun ES, Hanel A, Chan V, Nachtigall J, Harrison A, Aay N, Du H, Arcalas A, Galan A, Zhang J, Zhang W, Won KA, Tam D, Qian F, Wang T, Finn P, Ogilvie K, Rosen J, Aoyama R, Plonowski A, Cancilla B, Bentzien F, Yakes M, Mohan R, Lamb P, Nuss J, Kearney P.

J Med Chem. 2012 May 10;55(9):4322-35. doi: 10.1021/jm300122u. Epub 2012 Apr 19.

PMID:
22497444
17.

Expression of mRNA for growth hormone-releasing hormone and splice variants of GHRH receptors in human malignant bone tumors.

Busto R, Schally AV, Braczkowski R, Plonowski A, Krupa M, Groot K, Armatis P, Varga JL.

Regul Pept. 2002 Oct 15;108(2-3):47-53.

PMID:
12220726
18.

Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers.

Plonowski A, Schally AV, Busto R, Krupa M, Varga JL, Halmos G.

Peptides. 2002 Jun;23(6):1127-33.

PMID:
12126741
20.

Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215.

Szereday Z, Schally AV, Nagy A, Plonowski A, Bajo AM, Halmos G, Szepeshazi K, Groot K.

Br J Cancer. 2002 Apr 22;86(8):1322-7.

21.
22.

Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207.

Plonowski A, Schally AV, Nagy A, Groot K, Krupa M, Navone NM, Logothetis C.

Cancer Lett. 2002 Feb 8;176(1):57-63.

PMID:
11790454
23.

Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.

Plonowski A, Schally AV, Nagy A, Sun B, Halmos G.

Int J Oncol. 2002 Feb;20(2):397-402.

PMID:
11788908
24.

Hypothalamic hormones and cancer.

Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL, Halmos G.

Front Neuroendocrinol. 2001 Oct;22(4):248-91. Review.

PMID:
11587553
25.

Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238.

Plonowski A, Schally AV, Koppan M, Nagy A, Arencibia JM, Csernus B, Halmos G.

Cancer. 2001 Sep 1;92(5):1168-76.

PMID:
11571730
26.
27.

Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness.

Arencibia JM, Schally AV, Krupa M, Bajo AM, Nagy A, Szepeshazi K, Plonowski A.

Int J Oncol. 2001 Sep;19(3):571-7.

PMID:
11494038
28.

New analogs of somatostatin: inhibiting effectively GH, glucagon and insulin levels.

Baranowska B, Radzikowska M, Wasilewska-Dziubinska E, Plonowski A, Roguski K, Legowska A, Przybylski J.

Neuro Endocrinol Lett. 1999;20(3-4):237-244.

PMID:
11462119
29.

Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways.

Rekasi Z, Varga JL, Schally AV, Plonowski A, Halmos G, Csernus B, Armatis P, Groot K.

Peptides. 2001 Jun;22(6):879-86.

PMID:
11390017
30.

In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215.

Plonowski A, Nagy A, Schally AV, Sun B, Groot K, Halmos G.

Int J Cancer. 2000 Nov 15;88(4):652-7.

31.

Peptide analogs in the therapy of prostate cancer.

Schally AV, Comaru-Schally AM, Plonowski A, Nagy A, Halmos G, Rekasi Z.

Prostate. 2000 Oct 1;45(2):158-66. Review.

PMID:
11027415
32.

Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone.

Halmos G, Schally AV, Varga JL, Plonowski A, Rekasi Z, Czompoly T.

Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10555-60.

33.

High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers.

Halmos G, Schally AV, Sun B, Davis R, Bostwick DG, Plonowski A.

J Clin Endocrinol Metab. 2000 Jul;85(7):2564-71.

PMID:
10902809
34.
35.

Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.

Plonowski A, Schally AV, Nagy A, Kiaris H, Hebert F, Halmos G.

Cancer Res. 2000 Jun 1;60(11):2996-3001.

37.

Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome.

Baranowska B, Radzikowska M, Wasilewska-Dziubińska E, Kapliński A, Roguski K, Płonowski A.

Gynecol Endocrinol. 1999 Oct;13(5):344-51.

PMID:
10599552
38.

Correlation between 21 amino acid endothelin, intrafollicular steroids and follicle size in stimulated cycles.

Plonowski A, Kaplinski AP, Radzikowska M, Borowiec M, Baranowska B.

Hum Reprod. 1999 Sep;14(9):2323-7.

PMID:
10469703
39.

Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.

Plonowski A, Schally AV, Nagy A, Sun B, Szepeshazi K.

Cancer Res. 1999 Apr 15;59(8):1947-53.

40.

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.

Koppán M, Nagy A, Schally AV, Plonowski A, Halmos G, Arencibia JM, Groot K.

Prostate. 1999 Feb 1;38(2):151-8.

PMID:
9973101
41.
42.

[Case report presentation for treatment of pure red cell aplasia].

Giedrojć J, Janczarek B, Klimuk MB, Płonowski A, Bielawiec M.

Pol Arch Med Wewn. 1997 Sep;98(9):231-4. Polish.

PMID:
9557075
43.

Neuropeptide Y, galanin, and leptin release in obese women and in women with anorexia nervosa.

Baranowska B, Wasilewska-Dziubińska E, Radzikowska M, Płonowski A, Roguski K.

Metabolism. 1997 Dec;46(12):1384-9.

PMID:
9439531
44.

Are mu-opioid receptors involved in the control of endothelin-1 release from the pituitary gland in normal and dehydrated rats?

Płonowski A, Szymańska-Debińska T, Radzikowska M, Baranowska B, Woźniewicz B.

Regul Pept. 1997 Mar 26;69(2):89-94.

PMID:
9178351
45.

Impaired response of atrial natriuretic peptide to acute water load in obesity and in anorexia nervosa.

Baranowska B, Wasilewska-Dziubińska E, Radzikowska M, Płonowski A, Roguski K.

Eur J Endocrinol. 1995 Feb;132(2):147-51.

PMID:
7858731
46.
47.

[Evaluation of the antithrombotic effects of pentoxifylline, acetylsalicylic acid and low molecular weight heparin in the laser model of thrombosis].

Krupiński K, Breddin HK, Bielawiec M, Płonowski A.

Kardiol Pol. 1992 Mar;36(3):142-5. Polish.

PMID:
1318982
48.

Acute myelosclerosis--morphological and clinical analysis of the case. A review of literature.

Dziecioł J, Kemona A, Płonowski A, Sobaniec-Lotowska M, Sulkowski S, Musiatowicz B.

Patol Pol. 1992;43(4):189-91. Review.

PMID:
1283783

Supplemental Content

Loading ...
Support Center